Researchers at Washington University School of Medicine in St. Louis have discovered that mRNA cancer vaccines can call on a hidden backup immune cell when the usual frontline cell is missing. This overturns a long held assumption about how these vaccines work and could lead to more powerful treatments.
A backup immune cell steps in when the usual one is gone
For years, scientists believed that a specific type of dendritic cell called cDC1 was essential for mRNA cancer vaccines to trigger a strong T cell attack against tumors. The new study, published in Nature, tested that idea in mice. When the researchers removed cDC1 cells, the vaccines still worked. Another closely related dendritic cell took over the job and launched a powerful tumor fighting response.
How the vaccines train the immune system
mRNA cancer vaccines work by delivering genetic instructions that tell immune cells to produce small protein fragments. These fragments train T cells to recognize and destroy cancer cells while leaving healthy tissue alone. Dendritic cells are central to this process. They produce the protein fragments from the mRNA and present them to T cells. The discovery that a backup dendritic cell can do this job when cDC1 is absent gives vaccine developers new options.
Why this matters for future treatments
The study was led by senior author Kenneth M. Murphy, MD, PhD, a professor of pathology and immunology at WashU Medicine and a research member at Siteman Cancer Center. Murphy said the findings offer vaccine developers additional mechanistic insights to consider as they work to optimize these vaccines against tumor proteins. Experimental mRNA cancer vaccines are already being tested against melanoma, small cell lung cancer, bladder cancer, and other cancers. Understanding which immune cells are involved and how they coordinate the response could help researchers design more effective vaccines and tailor treatments for better patient outcomes.
